Adenocarcinoma: A unique cervical cancer

Gynecologic Oncology

Volumn 116, Issue 1, 2010, Pages 140-146

  Gien, Lilian T ^a   Beauchemin, Marie Claude ^a   Thomas, Gillian ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Adenocarcinoma; Cervix; Differences; Management; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; TOPOTECAN;

ADENOCARCINOMA; ADVANCED CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; FEMALE; HUMANS; UTERINE CERVICAL NEOPLASMS;

EID: 70749142744     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.09.040     Document Type: Review

References (60)

1. Eifel P.J., Morris M., Oswald M.J., Wharton J.T., and Delclos L. Adenocarcinoma of the uterine cervix: prognosis and patterns of failure in 367 Cases. Cancer 65 (1990) 2507-2514
2. Lai C.H., Hsueh S., Hong J.H., Chang T.C., Tseng C.J., Chou H.H., et al. Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery?. Int. J. Gynecol. Cancer 9 (1999) 28-36
3. Smith H.O., Tiffany M.F., Qualls C.R., and Key C.R. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States: a 24-year population-based study. Gynecol. Oncol. 78 (2000) 97-105
4. Sasieni P., and Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 357 (2001) 1490-1493
5. Wang S.S., Sherman M.E., Hildesheim A., Lacey Jr. J.V., and Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 100 (2004) 1035-1044
6. Sherman M.E., Wang S.S., Carreon J., and Devesa S.S. Mortality trends for cervical squamous and adenocarcinoma in the United States. Cancer 103 6 (2005) 1258-1264
7. Bray F., Carstensen B., Møller H., Zappa M., Zakelj M.P., Lawrence G., et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol. Biomark. Prev. 14 (2005) 2191-2199
8. Castellsagué X., Díaz M., De Sanjosé S., Muñoz N., Herrero R., Franceschi S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J. Natl. Cancer Inst. 98 (2006) 303-315
9. Eifel P.J., Burke T.W., Morris M., and Smith T.L. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage 1B cervical carcinoma. Gynecol. Oncol. 59 (1995) 38-44
10. Landoni F., Maneo A., Colombo A., Placa F., Milani R., Perego P., et al. Randomized study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350 (1997) 535-540
11. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer. N. Engl. J. Med. 340 (1999) 1137-1143
12. Sedlis A., Bundy B.N., Rotman M.Z., Lentz S.S., Muderspach L.I., and Zaino R.J. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage 1b carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. Gynecol. Oncol. 73 (1999) 177-183
13. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation, and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med. 340 (1999) 1154-1161
14. Rose P.G., Bundy B.N., Watkins J., et al. Concurrent cisplatin-based chemotherapy and radiotherapy for locally advanced cervical cancer. N. Engl. J. Med. 340 (1999) 1144-1153
15. Whitney C.W., Sause W., Bundy B.N., et al. A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J. Clin. Oncol. 17 (1999) 1339-1348
16. Landoni F., Maneo A., Cormio G., Perego P., Milani R., Caruso O., et al. Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study. Gynecol. Oncol. 80 (2001) 3-12
17. Peters W.A., Liu P.Y., Barrett R.J., Stock R.J., Monk B.J., Berek J.S., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early stage cancer of the cervix. J. Clin. Oncol. 18 (2000) 1606-1613
18. Eifel P.J., Winter K., Morris M., Levenback C., Grigsby P.W., Cooper J., et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01. J. Clin. Oncol. 22 (2004) 872-880
19. Lanciano R., Calkins A., Bundy B.N., Parham G., Lucci J.A., Moore D.H., et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 23 (2005) 8289-8295
20. Monk B.J., Wang J., Im S., Stock R.J., Peters W.A., Liu P.Y., et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol. Oncol. 96 (2005) 721-728
21. Rotman M., Sedlis A., Piedmonte M.R., Bundy B., Lentz S.S., Muderspach L.I., et al. A phase III randomized trial of postoperative pelvic irradiation in stage 1B cervical carcinoma with poor prognostic features: follow-up of a Gynecologic Oncology Group study. Int. J. Radiat. Oncol. Biol. Phys. 65 (2006) 169-176
22. Wang S.S., Sherman M.E., Silverberg S.G., Carreon J.D., Lacey J.V., Zaino R., et al. Pathological characteristics of cervical adenocarcinoma in a multi-center U.S.-based study. Gynecol. Oncol. 103 (2006) 541-546
23. Alfsen G.C., Reed W., and Abeler V.M. Reproducibility of classification in non-squamous cell carcinomas of the uteterine cervix. Gynecol. Oncol. 90 (2003) 282-289
24. The Bethesda System for reporting cervical/vaginal cytologic diagnoses: revised after the second National Cancer Institute workshop, April 29-30, 1991. Acta Cytol. 37 (1993) 115-124
25. International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int. J. Cancer 118 (2006) 1481-1495
26. Peters R.K., Chao A., Mack T.M., Thomas D., Bernstein L., and Henderson B.E. Increased frequency of adenocarcinoma of the uterine cervix in young women in Los Angeles County. J. Natl. Cancer Inst. 76 (1986) 423-428
27. Smith J.S., Green J., Berrington de Gonzalez A., Appleby P., Peto J., Plummer M., et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361 (2003) 1159-1167
28. Grigsby P.W., Perez C.A., Kuske R.R., Camel H.M., Kao M.S., Galakatos A.E., et al. Adenocarcinoma of the uterine cervix: lack of evidence for a poor prognosis. Radiother. Oncol. 12 (1988) 289-296
29. Shingleton H.M., Bell M.C., Fremgen A., Chmiel J.S., Russell A.H., Jones W.B., et al. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoa, and adenosquamous cell carcinoma of the cervix?. Cancer 76 (1995) 1948-1955
30. Look K.Y., Brunetto V.L., Clarke-Pearson D.L., Averette H.E., Major F.J., Alvarez R.D., et al. An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol. Oncol. 63 (1996) 304-311
31. Kilgore L.C., Soong S.J., Gore H., et al. Analysis of prognostic features in adenocarcinoma of the cervix. Gynecol. Oncol. 31 (1998) 137-148
32. Alfsen G.C., Kristensen G.B., Skovlund E., Pettersen E.O., and Abeler V.M. Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix. Cancer 92 (2001) 2471-2483
33. Lee K.B.M., Lee J.M., Park C.Y., Lee K.B., Cho H.Y., and Ha S.Y. What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study. Int. J. Gynecol. Cancer 16 (2006) 1569-1573
34. Berek J.S., Hacker N.S., Fu Y.S., et al. Adenocarcinoma of the uterine cervix: histologic variables associated with lymph node metastasis and survival. Obstet. Gynecol. 65 (1985) 46-52
35. Kleine W., Rau K., Schwoeorer D., and Pfleiderer A. Prognosis of adenocarcinoma of the cervix uteri: a comparative study. Gynecol. Oncol. 35 (1989) 145-159
36. Hopkins M.P., and Morley G.W. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet. Gynecol. 77 (1991) 912-917
37. Chen R.J., Lin Y.H., Chen C.A., Huang S.C., Chow S.N., and Hsieh C.Y. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol. Oncol. 73 (1999) 184-190
38. Nakanishi T., Ishikawa H., Suzuki Y., Inoue T., Nakamura S., and Kuzuya K. A comparison of prognoses of pathologic stage IB adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol. Oncol. 79 (2000) 289-293
39. Irie T., Kigawa J., Minagawa Y., Itamochi H., Sato S., Akeshima R., et al. Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur. J. Surg. Oncol. 26 (2000) 464-467
40. Takeda N., Sakuragi N., Takeda M., Okamoto K., Kuwabara M., Negishi H., et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet. Gynecol. Scand. 81 (2002) 1144-1151
41. Davy M.L.J., Dodd T.J., Luke C.J., and Roder D.M. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet. Gynecol. 101 (2003) 38-45
42. Baalbergen A., Ewing-Graham P.C., Hop W.C.J., Struijk P., and Helmerhorst T.J.M. Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol. Oncol. 92 (2004) 262-267
43. Marchiole P., Benchaib M., Buenerd A., Lazlo E., Dargent D., and Mathevet P. Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation): a comparative study with laparoscopic-assisted vaginal radical hysterectomy (LARVH). Gynecol. Oncol. 106 (2007) 132-141
44. Gallup D.G., Harper R.H., and Stock R.J. Poor prognosis in patients with adenosquamous cell carcinoma of the cervix. Obstet. Gynecol. 65 (1985) 416-422
45. Farley J.H., Hickey K.W., Carlson J.W., Rose G.S., Kost E.R., and Harrison T.A. Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma. Cancer 97 (2003) 2196-2202
46. Grisaru D., Covens A., Chapman B., Shaw P., Colgan T., Murphy J., et al. Does histology influence prognosis in patients with early-stage cervical carcinoma. Cancer 92 (2001) 2999-3004
47. Harrison T.A., Sevin B.U., Koechili O., Nguyen H.N., Averette H.E., Penalver M., et al. Adenosquamous carcinoma of the cervix: prognosis in early stage disease treated by radical hysterectomy. Gynecol. Oncol. 50 (1993) 310-315
48. Dos Reis R., Frumovitz M., Milam M.R., Capp E., Sun C.C., Coleman R.L., et al. Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecol. Oncol. 107 (2007) 458-463
49. Eifel P.J., Burke T.W., Delclos L., Wharton J.T., and Oswald M.J. Early stage I adenocarcinoma of the uterine cervix: treatment results in patients with tumors ≤4 cm in diameter. Gynecol. Oncol. 41 (1991) 199-205
50. Delgado G., Bundy B., Zaino R., Sevin B.U., Creasman W.T., and Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol. Oncol. 38 (1990) 352-357
51. Shimada M., Kiwaga J., Nishimura R., Yamaguchi S., Kuzuya K., Nakanishi T., et al. Ovarian metastasis in carcinoma of the uterine cervix. Gynecol. Oncol. 101 (2006) 234-237
52. Drescher C.W., Hopkins M.P., and Roberts J.A. Comparison of the pattern of metastatic spread of squamous cell cancer and adenocarcioma of the uterine cervix. Gynecol. Oncol. 33 (1989) 340-343
53. Lea J.S., Coleman R.L., Garner E.O., Duska L.R., Miller D.S., and Schorge J.O. Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. Gynecol. Oncol. 91 (2003) 558-562
54. Curtin J.P., Blessing J.A., Webster K.D., Rose P.G., Mayer A.R., Fowler W.C., et al. Paclitaxel, an active agent in nonsquamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 19 (2001) 1275-1278
55. Long H.J., Bundy B.N., Grendys E.C., Benda J.A., McMeekin D.S., Sorosky J., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 23 (2005) 4626-4633
56. Nagao S., Fujiwara K., Oda T., Ishikawa H., Koike H., Tanaka H., et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer: a pilot study. Gynecol. Oncol. 96 (2005) 805-809
57. Kastratis E., Bamias A., Efstathiou E., Gika D., Bozas G., Zorzou P., et al. The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. Gynecol. Oncol. 99 (2005) 376-382
58. del Campo J.M., Prat A., Gil-Moreno A., Perez J., and Parera M. Update on novel therapeutic agents for cervical cancer. Gynecol. Oncol. 110 (2008) S72-S76
59. Kurtz J.E., Hardy-Bessard A.C., Deslandres M., Lavau-Denis S., Largillier R., Roemer-Becuwe C., et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol. Oncol. 113 (2009) 16-20
60. Monk B.J., Sill M.W., Burger R.A., Gray H.J., Buekers T.E., and Roman L.D. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J. Clin. Oncol. 27 (2009) 1069-1074